At the March 9 and 10, 2017 Genetic Alliance Conference, Celiac Disease Foundation worked to determine best strategies to help grow our iCureCeliac® patient registry, and to encourage patients and their family members to engage in the research process to influence the future of celiac disease research toward treatments and a cure.
We fight to improve the lives of all affected by celiac disease and non-celiac gluten/wheat sensitivity NOW
At the March 5 and 6, 2017 Digestive Disease National Coalition Public Policy Forum, Celiac Disease Foundation, together with representatives from digestive disease organizations across the United States, developed common agendas to influence healthcare policy.
Celiac Disease Foundation, in partnership with the University of Southern California (USC) Keck School of Medicine, and CDF Board member Dr. Michael S. Karp, Chief of the Division of Geriatric, Hospital, Palliative and General Internal Medicine, is proud to launch a pioneering celiac disease training program for Internal Medicine residents. This program is made possible […]
ImmusanT, a Cambridge, MA-based biotechnology company, has announced that Nexvax2®, an immunotherapy drug designed to protect celiac disease patients from gluten exposure, has successfully completed a Phase 1b clinical trial and is advancing to a Phase 2 trial. Currently, strict, lifetime adherence to a gluten-free diet is the only disease management protocol for celiac disease […]
In 1992, M.N. Marsh published a study aimed at measuring degrees of change seen in the structure of intestinal villi under microscopic scrutiny. Villi are finger-like projections which line the intestinal walls; their thin walls and large surface area are what allow for efficient absorption and digestion of nutrients. In patients with celiac disease, the […]
In addition to improving treatments and finding a cure for celiac disease, iCureCeliac® is helping researchers appreciate the realities of living with celiac disease, helping to influencing what they choose to research and why.